EUVIMEDEUVIMED entdecken
EditorialOpen Access

Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia

Iván López-Ibor, Hugh Humphery, Gustavo Tafet

Cureus · 21.08.2026

DOI: 10.7759/cureus.114933 ↗

Kurz gefasst

Editorial in der Zeitschrift Cureus, erschienen am 21.08.2026. Verfasst von Iván López-Ibor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, South Florida Integrative Medicine, Miami, USA. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People with schizophrenia experience markedly reduced life expectancy, driven largely by cardiometabolic disease, and several of the most effective antipsychotics are also among those most likely to promote weight gain. Weight gain is among the adverse effects patients find least acceptable and one they frequently cite when they abandon treatment, which links metabolic harm directly to the non-adherence that precipitates relapse. Glucagon-like peptide-1 receptor agonists, now supported by randomized trials in schizophrenia-spectrum populations, reduce weight and metabolic burden without destabilizing psychiatric symptoms. In this editorial, we argue that their most consequential effect in serious mental illness may not be the weight they remove but the treatment they help patients keep taking: by neutralizing the adverse effect patients most resent, these agents may protect antipsychotic adherence itself. We call for trials that adopt adherence and discontinuation as endpoints and for psychiatry to reclaim ownership of cardiometabolic prescribing.

Schlagwörter

Stichwörter der Autor:innen

antipsychotic-induced weight gaincardiometabolic riskglucagon-like peptide-1 receptor agonistsmedication adherenceschizophreniasemaglutide

Autor:innen und Institutionen

  • Department of Psychiatry, South Florida Integrative Medicine, Miami, USA.
  • Department of Psychiatry, López Ibor Clinic, Madrid, ESP.
  • Department of Psychology, Dr. Esquerdo Sanatorium, Madrid, ESP.
  • Department of Psychiatry, Dr. Leon's Clinic, Madrid, ESP.
  • Department of Psychiatry, Herbert Wertheim College of Medicine, Florida International University, Miami, USA.
  • Department of Psychiatry, Texas A&M University - Central Texas, Killeen, USA.

Zitieren

APA

López-Ibor, I., Humphery, H., & Tafet, G. (2026). Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia. Cureus. https://doi.org/10.7759/cureus.114933

Vancouver

López-Ibor I, Humphery H, Tafet G. Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia. Cureus. 2026. doi:10.7759/cureus.114933

BibTeX
@article{LpezIbor2026,
  author = {López-Ibor, Iván and Humphery, Hugh and Tafet, Gustavo},
  title = {Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.114933}
}
Kostenlos starten →